CYRAMZA 10 MG
RAMUCIRUMAB : 10 MG · DIN 02443805 · ELI LILLY CANADA INC
Health Canada status: MARKETED
What is CYRAMZA?
CYRAMZA 10 MG contains RAMUCIRUMAB : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02443805, held by ELI LILLY CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 10-Sep-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CYRAMZA used for?
Treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02443805 |
|---|---|
| Brand name | CYRAMZA |
| Generic / active ingredient | RAMUCIRUMAB : 10 MG |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01FG02 RAMUCIRUMAB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Sep-2015 |
| Original market date | 2015-09-10 00:00:00 |
How is it administered?
8 mg/kg every 2 weeks as an IV infusion over ~60 mins. In combination with paclitaxel: 8 mg/kg on days 1 and 15 of a 28-day cycle prior to paclitaxel (80 mg/m2 on days 1, 8, 15).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store vials in a refrigerator at 2°C to 8°C. Keep vial in outer carton to protect from light. Do not freeze or shake.
How is it supplied?
10 mL or 50 mL single-use vials. Each vial contains either 100 mg or 500 mg ramucirumab (10 mg/mL). Vials are individually packaged in a carton.
Contraindications
Known hypersensitivity to ramucirumab or to any other ingredient used in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Increased risk of hemorrhage (including GI), gastrointestinal perforations, and impaired wound healing. Risk of arterial thromboembolic events, hypertension, heart failure, and PRES.
Who else supplies RAMUCIRUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RAMUCIRUMAB appears in 15 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.